Advances in Pharmacotherapy of Late-Life Depression.

Published online

Journal Article (Review)

This paper reviews recent research on late-life depression (LLD) pharmacotherapy, focusing on updated information for monotherapy and augmentation treatments. We then review new research on moderators of clinical response and how to use the information for improved efficacy. RECENT FINDINGS: A recent review shows that sertraline, paroxetine, and duloxetine were superior to placebo for the treatment of LLD. There is concern that paroxetine could have adverse outcomes in the geriatric population due to anticholinergic properties; however, studies show no increases in mortality, dementia risk, or cognitive measures. Among newer antidepressants, vortioxetine has demonstrated efficacy in LLD, quetiapine has demonstrated efficacy especially for patients with sleep disturbances, and aripiprazole augmentation for treatment resistance in LLD was found to be safe and effective. Researchers have also been identifying moderators of LLD that can guide treatment. Researchers are learning how to associate moderators, neuroanatomical models, and antidepressant response. SSRI/SNRIs remain first-line treatment for LLD. Aripiprazole is an effective and safe augmentation for treatment resistance. Studies are identifying actionable moderators that can increase treatment response.

Full Text

Duke Authors

Cited Authors

  • Beyer, JL; Johnson, KG

Published Date

  • April 7, 2018

Published In

Volume / Issue

  • 20 / 5

Start / End Page

  • 34 -

PubMed ID

  • 29627920

Pubmed Central ID

  • 29627920

Electronic International Standard Serial Number (EISSN)

  • 1535-1645

Digital Object Identifier (DOI)

  • 10.1007/s11920-018-0899-6

Language

  • eng

Conference Location

  • United States